

**Appendix 4C**

**Quarterly report**  
**for entities admitted**  
**on the basis of commitments**

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

STEMCELL UNITED LIMITED

ABN

57 009 104 330

Quarter ended ("current quarter")

30 June 2016

**Consolidated statement of cash flows**

<b>Cash flows related to operating activities</b>	Current quarter	Year to date (12 months)
	A\$	A\$
1.1 Receipts from customers	-	248,705
1.2 Payments for (a) staff costs	(53,347)	(200,696)
(b) advertising and marketing		-
(c) research and development		(4,586)
(d) leased assets	(21,338)	(61,293)
(e) other working capital	(7,779)	(945,976)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	734	12,268
1.5 Interest and other costs of finance paid	(3,172)	(4,048)
1.6 Income taxes paid	(9,017)	(9,017)
1.7 Other (provide details if material)	-	-
<b>Net operating cash flows</b>	<b>(93,919)</b>	<b>(964,643)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

	Current quarter A\$	Year to date (12 months) A\$
1.8 Net operating cash flows (carried forward)	<b>(93,919)</b>	<b>(964,643)</b>
<b>Cash flows related to investing activities</b>		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	(2,500,000)
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	(163,818)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (Cash acquired on acquisition of subsidiary)	-	86,238
<b>Net investing cash flows</b>	-	(2,577,580)
<b>1.14 Total operating and investing cash flows</b>	<b>(93,919)</b>	<b>(3,542,223)</b>
<b>Cash flows related to financing activities</b>		
1.15 Proceeds from issues of shares, options, etc.	-	681,600
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	16,634
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Other (payments relating to share issue cost)	-	(425,119)
<b>Net financing cash flows</b>	-	273,115
<b>Net increase (decrease) in cash held</b>	<b>(93,919)</b>	<b>(3,269,108)</b>
1.21 Cash at beginning of quarter/year to date	344,510	3,554,300
1.22 Exchange rate adjustments to item 1.20	22,306	(12,295)
1.23 <b>Cash at end of quarter</b>	<b>272,897</b>	<b>272,897</b>

+ See chapter 19 for defined terms.

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter A\$
1.24	Aggregate amount of payments to the parties included in item 1.2	28,500
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Director fees :	A\$19,500
Professional fees:	A\$9,000
Total:	A\$28,500

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

Shares issued for purchase of subsidiary: A\$36,000,000 Options issued to fund raising Lead Manager: A\$148,000
--

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A
-----

**Financing facilities available**

*Add notes as necessary for an understanding of the position.*

		Amount available A\$	Amount used A\$
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

---

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter A\$	Previous quarter A\$
4.1 Cash on hand and at bank	272,897	344,510
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
<b>Total: cash at end of quarter (item 1.23)</b>	<b>272,897</b>	<b>344,510</b>

**Acquisitions and disposals of business entities**

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	Stemcell United Pte Ltd	
5.2 Place of incorporation or registration	Singapore	
5.3 Consideration for acquisition or disposal	A\$38,500,000	
5.4 Total net assets	A\$655,101	
5.5 Nature of business	Stemcell United Pte Ltd is a biotechnology company which focuses on the extraction, culture, reproduction, and growth of plant stem cells for medicinal health and beauty applications in Traditional Chinese Medicine. This includes sourcing and production of Daemonorops Draco Blume extract, a plant that grows in the tropical rainforest of Indonesia, to traders and pharmaceutical companies in Hong Kong and China.	

---

+ See chapter 19 for defined terms.

**Compliance statement**

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does ~~/does not\*~~ ~~(delete one)~~ give a true and fair view of the matters disclosed.

Sign here:

  
.....  
(Director/~~Company secretary~~)

Date: 29 July 2016

Print name: Chow Yee Koh

**Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

---

+ See chapter 19 for defined terms.